

01 Sep 2024 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: summer ADC dealmaking continues apace; a look at cell therapies in Japan; Pfizer's new US digital consumer platform; Galapagos's US point of care CAR-T study; and Novartis partners with Lindy on biologics delivery.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 30 August 2024, including: summer ADC dealmaking continues apace; a look at cell therapies in Japan; [Pfizer Inc.](#)'s new US digital consumer platform; [Galapagos NV](#)'s US point of care CAR-T study; and [Novartis AG](#) partners with [Lindy Biosciences](#) on biologics delivery.

This and all our other podcasts are available on the *Citeline* channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Five Recent Deals Show ADCs Aren't Cooling Off For Summer](#)" - Scrip, 23 Aug, 2024.)

(Also see "[Progress Or Hype? A Decade Of Cell Therapy In Japan](#)" - Scrip, 25 Aug, 2024.)

(Also see "[Pfizer Unveils New End-To-End Digital Consumer Platform](#)" - Scrip, 27 Aug, 2024.)

(Also see "[Galapagos Expands Point-Of-Care CAR-T Study To The US](#)" - Scrip, 23 Aug, 2024.)

(Also see "[Honey, I Shrunk The Drugs: Novartis, Lindy Partner On Biologics Delivery](#)" - Scrip, 28

Aug, 2024.)

[Click here to explore this interactive content online](#) 